|
|
NIVALIN
-
| StockNo |
Product description |
| EB0280-418-08 |
NIVALIN
AMPOULE 1 MG/1ML (0.1%) |
| EB0280-418-18 |
NIVALIN
AMPOULE 10 MG/1ML (1%) |
| EB0280-418-17 |
NIVALIN
AMPOULE 2.5 MG/1ML (0.25%) |
| EB0280-418-16 |
NIVALIN
AMPOULE 5 MG/1ML (0.5%) |
| EB0280-418-27 |
NIVALIN
TABL 1 MG X 50 |
| EB0280-418-09 |
NIVALIN
TABL 5 MG X 50 |
| EB0280-418-41 |
NIVALIN
TABL 10 MG X 20 |
| EB0280-418-28 |
NIVABEX
SYRUP W/ VIT B 125 ML |
| EB0280-418-29 |
NIVALIN
SYRUP 125 ML (0.5 MG/1ML) |
-
www.nivalin.com
- COMPOSITION:
Galanthamine hydrochloride 1 mg/1 ml; 2.5 mg/l ml; 5 mg/l ml; 10
mg/l ml in one ampoule and 1 mg and 5 mg in one tablet
ACTION:
Alkaloid obtained from the Bulgarian snowdrop Galanthus nivalis var.
gracilis, similar in pharmacologic properties to physostigmine and
neostigmine. It acts as a strong reversible inhibitor of
cholinesterase and increases the receptor sensitivity to
acethylcholine. It facilitates stimulation conduction in the
neuromuscular synapses and restores neuromuscular conduction when
blocked bynondepolarizing neuromuscular blockers. Nivalin passes
through the hematoencephalic barrier, facilitates impulse conduction
in CNS and enhances excitation processes. It enhances the tone of
the smooth muscles and enhances the secretion of the
gastrointestinal and perspiration glands, provokes contraction of
the pupil. It acts as antagonist to the suppressing action of
morphine and of its structural analogues on the respiratory center.
PHARMACOKINETICS:
Nivalin is absorbed very quickly, therapeutic plasma concentrations
are reached 25-30 min after oral or subcutaneous application and
last for 5 h.
INDICATIONS:
Poliomyelitis - immediately after bringing down the temperature
during both restorative and residual periods. Myasthenia, myopathy,
motor and sensory disturbances connected with diseases and traumatic
injuries of the nervous system, polyneuritis, radiculitis,
radiculoneuritis, myelitis; after-effects of diseases of the
cerebral vessels; lower tone of the smooth muscles of the
gastrointestinal and urinary tracts.
CONTRAINDICATIONS:
Bronchial asthma, bradycardia, stenocardia, cardiac decompensation,
epilepsy, hyperkinesis. |
SIDE EFFECTS:
In adequate doses, the preparation is well tolerated. Overdosage and
individually increased sensitivity may cause abundant salivation,
perspiration, vomiting or dizziness. If such symptoms appear, the
daily dose is reduced or the treatment is discontinued for 2-3 days,
to be continued later with lower doses. If necessary, atropine may
be used as an antidote.
DOSAGE AND ADMINISTRATION:
The daily dose for adults at subcutaneous application is
0.00125-0.0025 (= 0.25-3 ml of 0.5 % solution); the treatment of
children is carried out by scheme according to the age from
0.00025-0.001 (one-year old) to 0.0012-0.0125 (15-year old). The
preparation is better tolerated by children. The duration of the
treatment depends on the specificities of the disease and on the
effectiveness of the treatment, usually lasting 40-50 days. The
treatment course may be applied 2-3 times a year at an interval of
1-1 1/2 months. If higher doses are necessary, the daily dose may be
given in two applications for better tolerance.
As an anticurare drug, Nivalin is injected intravenously: adults -
0.01-0.02; children - according to age.
The tablets are administered 3-4 times daily at total daily dose of
5-10 mg, always after meals, for 4-5 weeks. The high doses are
applied over a shorter period of time.
The preparation is applied also by means of electrophoresis.
MEDICINAL FORM AND PACKAGE:
Ampoules of 1 mg/ l ml (0.1 %), 2.5 mg/ l ml (0.25 %), 5 mg/ l ml
(0.5 %) and 10 mg/ l ml (1 %) in packs of 10, 50 and 100;
Tablets of 1 mg and 5 mg - in packs of 50.
STORAGE:
At moderate temperature (15-30° C).
EXPIRY:
5 (five) years.
|
|
|
